Clinical Study On Jinghuaweikang Capsule Combined With Bismuth Quadruple Therapy For Helicobacter Pylori Positive Functional Dyspepsia

Objective To observe the efficacy and safety of Jinghuaweikang capsule combined with Bismuth Quadruple Therapy in the treatment of HP-positive functional dyspepsia,and to explore the eradication rate,recurrence rate and improvement of symptoms of HP-positive functional dyspepsia treated with integrated traditional Chinese and Western medicine.Methods One hundred patients with functional dyspepsia and HP-positive by endoscopy from January to June 2018 were randomly divided into two groups:A(50 cases)and B(50 cases).Group A:esomeprazole 20mg+amoxicillin 1000mg + furazolidone 100mg+bismuth potassium citrate 20mg twice a day for 14 days;group B:esomeprazole 20mg+amoxicillin 1000mg+furazolidone 100mg+bismuth potassium citrate 20mg twice a day;group d15-d44:Jinghuaweikang capsule 160mg three times a day for 44 days.The C14 breath test was reexamined one month and six months after the treatment.The improvement of symptoms(mid-upper abdominal pain,postprandial fullness discomfort,early satiety,mid-upper abdominal burning)before and after treatment were observed and recorded,and the effectiveness and safety of the treatment were evaluated.Results(1)The basic data of age,sex,history of smoking and alcohol,past history and family history of the two groups were statistically analyzed.There was no significant difference between the two groups(P>0.05),which was comparable.(2)The eradication rate of HP was 91.3%in group A and 95.7%in group B,suggesting that the eradication rate was high in group B,but there was no significant difference between the two groups(P>0.05).For the successful eradication patients after 6 months of treatment,re-check the breathing test to check whether there was a recurrence.The recurrence rate of group A was 5.0%,and that of group B was 2.3%.This indicates that the recurrence rate of group A was high,but there was no significant difference between the two groups(P>0.05).(3)The condition of symptomatic improvement after treatment:Upper and middle abdominal pain:before treatment,there was no significant difference in symptom score between the two groups(P>0.05),which was comparable;after treatment,the symptom score of group B was significantly lower than that of group A(P<0.05).Intra-group comparison:After treatment,the symptom scores of A and B groups decreased compared with before treatment,and the difference was statistically significant(P<0.05).Postprandial fullness and distension:There was no significant difference in symptom score between the two groups before treatment(P>0.05),which was comparable;after treatment,the symptom score of group B was significantly lower than that of group A(P<0.05).Intra-group comparison:After treatment,the symptom scores of A and B groups decreased compared with before treatment,and the difference was statistically significant(P<0.05).Early satiety:comparison between the two groups:before treatment,there was no significant difference in symptom score between the two groups(P>0.05),which was comparable;after treatment,the symptom score of group B was significantly lower than that of group A(P<0.05).Intra-group comparison:After treatment,the symptom score of group A decreased,but there was no significant difference(P>0.05),while that of group B decreased,with significant difference(P<0.05).Burning sensation of mid-upper abdomen:There was no significant difference in symptom score between the two groups before treatment(Py 0.05),which was comparable;after treatment,the symptom score of group B was significantly lower than that of group A(P<0.05).Intra-group comparison:After treatment,the symptom scores of A and B groups decreased compared with before treatment,and the difference was statistically significant(P<0.05).(4)Comparisons of total symptom scores between the two groups:before treatment,there was no significant difference in total symptom scores between the two groups(P>0.05),which was comparable;after treatment,the total symptom scores of group B were significantly lower than those of group A,and the difference was statistically significant(P<0.05).Intra-group comparison:After treatment,the total score of symptoms in group A and group B decreased compared with that before treatment,and the difference was statistically significant(P<0.05).(5)The incidence of adverse reactions was 6.52%in group A and 8.69%in group B,suggesting that the incidence of adverse reactions in group B was high,but there was no significant difference between the two groups(P>0.05).Discussion Jinghuaweikang capsule combined with Bismuth quadruple therapy and Bismuth quadruple therapy have higher eradication rate and lower incidence of adverse reactions for HP,and are safe for clinical use;but Jinghuaweikang capsule combined with Bismuth quadruple therapy is better than Bismuth quadruple therapy for HP-positive functional dyspepsia.The combination of traditional Chinese and Western medicine for good patients provides an effective way of thinking and basis.